Multicenter Retrospective Analysis of Chemotherapy for Advanced Pancreatic Acinar Cell Carcinoma: Potential Efficacy of Platinum- and Irinotecan-Containing Regimens.

The aim of this multicenter retrospective study was to identify the optimal chemotherapeutic regimen for advanced pancreatic acinar cell carcinoma (PACC). Fifty-eight patients with histopathologically confirmed advanced PACC who had received chemotherapy between 1996 and 2013 were enrolled. The clinical characteristics of the patients and the treatment efficacy data were collected from the medical records at 16 Japanese institutions, using standardized data collection instrument. The most commonly selected treatment regimens were gemcitabine-, fluoropyrimidine-, platinum-, and irinotecan-containing regimens. The overall response rate in the patients who received first-line chemotherapy were 7% and 38%, respectively, and the median overall survival was 13.2 months. When the data for all the treatment lines were aggregated, the response rates to gemcitabine-, fluoropyrimidine-, platinum-, and irinotecan-containing regimens were 7%, 18%, 40%, and 29%, respectively. The overall survival tended to be better in patients who had received a platinum-containing regimen (hazard ratio, 0.50; 95% confidence interval, 0.23-1.11; P = 0.08) or irinotecan-containing regimen (hazard ratio, 0.42; 95% confidence interval, 0.15-1.19; P = 0.09) at least once in the treatment course as compared with those who had not. Our findings suggested that platinum- and irinotecan-containing regimens exhibited some potential efficacy in patients with advanced PACC.

Informations de copyright

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc.

Déclaration de conflit d'intérêts

M.I. has a board membership of Nihon Servier, Novartis, Bayer, Eisai, Eli Lilly, Chugai, AstraZeneca, Shire, Nano Carrier, and ASLAN, grants from Yakult, Ono, Bristol-Myers Squibb, Nano Carrier, Novartis, Bayer, Eisai, Eli Lilly, MSD, Chugai, AstraZeneca, J-Pharma, Pfizer, ASLAN, Merck Serono, and Takeda, payment for lectures from Taiho, Yakult, Nihon Servier, Novartis, Bayer, Eisai, Eli Lilly, Dainippon Sumitomo, MSD, Mylan, Chugai, Astellas, EA pharma, Gilead, Otsuka, and Teijin. Y.K. has a payment for lectures from Taiho, Chugai, Sanofi, Bristol-Myers Squibb, and Eli Lilly. Expert Testimony from AstraZeneca, grants from Ono, Nano Carrier, BeiGene, Taiho, and Takeda. S.K. has a payment for lectures from Bayer, Boston Scientific, Daiichi Sankyo, Eisai, Kyowa Hakko Kirin, Taiho, and Teijin. M.O. has grants from Astellas, Ono, Taiho, MSD, Incyte and Yakult, payment for lectures from Taiho, Yakult, and Novartis. A.K. has a Consulting fee from Taiho. M.U. has a grants from Astellas, Taiho, Daiichi Sankyo, Eisai, AstraZeneca, Ono, MSD, Merck Serono, Dainippon Sumitomo, Incyte, ASLAN and Yakult, payment for lectures from Taiho, Yakult, AstraZeneca, Teijin, Merck Serono, Nipro, MSD, and Daiichi Sankyo. C.M. has a grants from Yakult, Eisai, Taiho, Merck biopharma, AstraZeneca and J-Phama, payment for lectures from MSD, Yakult, Novartis, Teijin, Taiho and AbbVie. J.F. has a Consultancy of Fujifilm, Ono, Yakult, MSD, Merck Bio, J-Pharma, MSD, Chugai, Taiho, Nihon Servier, AstraZeneca, AbbVie, and Astellas, grants from Ono, MSD, Sumitomo Dainippon, J-Pharma, Yakult, AstraZeneca, Daiichi Sankyo, Eisai, Bayer, Pfizer, Nano Carrier, Kyowa Hakko Kirin, Taiho, Chugai, Sanofi, Takeda, Mochida, Astellas, and Eli Lilly Japan, payment for lectures from Eisai, Bayer, Taiho, Ono, Novartis, Yakult, Teijin, Shionogi, EA pharma, Eli Lilly Japan, Takeda, Chugai, Mochida, Nihon Servier, Sanofi, Fujifilm Toyama, Nobel pharma, Pfizer, Sawai, Daiichi Sankyo, Sumitomo Dainippon, Merck Serono, Nippon Kayaku, MSD, Shire, and Kyowa Hakko Kirin. The other authors declare no conflict of interest.